Main Title : Update on Diabetes Mellitus
Plenary Lecture I  (Fri. 9, 09:50~10:50, Room A)
ÁÂÀå: ¼ÕÈ£¿µ
Insulin resistance and beta cell failure in type 2 diabetes Domenico Accili
(Columbia University, USA)
Plenary Lecture II  (Sat. 10, 10:00~11:00, Room A)
ÁÂÀå: ÃÖ¿µ±æ
The TORC family of CREB coactivators: Regulators of energy balance Marc Montminy
(The Salk Institute, USA)
Main Symposia
I. Beta Cell and Diabetes Mellitus (English)  (Fri. 9, 11:00~13:00, Room A)
ÁÂÀå: ±è±¤¿ø, ÃÖµ¿¼·
1. Regulation of insulin granule dynamics Susumu Seino
(Kobe University, Japan)
2. Pancreatic islet imaging: What do we want to know and how do we measure it? Alvin C. Powers
(Vanderbilt University, USA)
3. Membrane trafficking during insulin secretion John C. Hutton
(Barbara Davis Center, USA)
4. Type 1 DM suppression and beta-cell proliferation in novel
    leptin receptor mutation NOD mice
ÀÌöȣ
(Çѱ¹»ý¸í°øÇבּ¸¿ø)
II. Pathogenesis of Type 2 Diabetes Mellitus
   - Inflammation, Mitochondria and ER Stress (English)
(Fri. 9, 15:10~17:10, Room A)
ÁÂÀå: ±è¼±¿ì, À̱â¾÷
1. Obesity, Inflammation and Macrophages:
    Role of chemokines in macrophage accumulation in
    adipose tissue
Anthony W. Ferrante
(Columbia University, USA)
2. Role of Lipin in hepatic insulin signaling ±¸½Âȸ (¼º±Õ°üÀÇ´ë)
3. CRIF1 links genomic stresses with mitochondrial responses: The possible roles of CRIF1 in cellular senescence and insulin resistances. ¼Û¹ÎÈ£ (Ãæ³²ÀÇ´ë)
4. ER stress and ¥â-cell dysfunction ÀÌÀÎ±Ô (°æºÏÀÇ´ë)
III. Clinical Update on Diabetes (Sat. 10, 11:10~13:10, Room A)
ÁÂÀå: ±èÁø¿ì, À̺´µÎ
1. ´ç´¢º´¼º ¸Á¸·Áõ Ä¡·áÀÇ ÃÖ½ÅÁö°ß °­¼¼¿õ (¼º±Õ°üÀÇ´ë)
2. ´ç´¢º´ ȯÀÚ¿¡¼­ ÇãÇ÷¼º ½ÉÁúȯÀÇ ºñħ½ÀÀû Áø´ÜÀÇ ÃÖ½ÅÁö°ß ÃÖ»óÀÏ (¼­¿ïÀÇ´ë)
3. ´ç´¢º´ ȯÀÚ¿¡¼­ ÇãÇ÷¼º ½ÉÁúȯÀÇ Ä¡·á ÀÌöȯ (¿ï»êÀÇ´ë)
4. New anti-diabetic drugs ¿ìÁ¤Åà (°æÈñÀÇ´ë)
Special lecture I (Fri. 9, 11:00~12:00, Room B)
ÁÂÀå: ÀÌÇöö
Oxidative stress defenses and aging in C. elegans T. Keith Blackwell
(Harvard Medical School, USA)
Special lecture II (Fri. 9, 12:00~13:00, Room B)
ÁÂÀå: ±è¿µ¼³
Role of insulin in vascular health Kieren J. Mather
(Indiana University, USA)
2006 ¼³¿ø ¿¬±¸ºñ ¹× ÁßÁ¡°úÁ¦ ¿¬±¸ºñ º¸°í (Fri. 9, 14:00~15:00, Room A)
ÁÂÀå: ¼ÕÈ£¿µ
2006 ¼³¿ø ¿¬±¸ºñ º¸°í
Role of PGC1 in vascular cell and beta cell
ÀÌÀÎ±Ô (°æºÏÀÇ´ë)
ÁßÁ¡°úÁ¦ ¿¬±¸ºñ º¸°í
1. Çѱ¹ÀÎ Àӽżº ´ç´¢º´ ¿©¼ºÀÇ Á¦2Çü ´ç´¢º´ ¹ß»ý±âÀü: À¯ÀüÀû °¨¼ö¼º°ú ³»Àå Áö¹æÀÇ ¿ªÇÒ

ÀåÇÐö (¼­¿ïÀÇ´ë)
2. Web-based comprehensive information system for self-management of diabetes mellitus À¯ÇüÁØ (ÇѸ²ÀÇ´ë)
3. Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in ZDF rats ÀÌÇöö (¿¬¼¼ÀÇ´ë)


¿ì¼ö Æ÷½ºÅÍ ½Ã»ó (Sat. 10, 13:10~13:20, Room A)
½Ã»ó: ¹Ú¼º¿ì, ÁøÇà: ¹ÚÁß¿­


Commitments and Study Groups Symposia
±³À°ÀÚ Çмú°­ÁÂ
ÁÖÁ¦: Insulin
(Fri. 9, 11:00~13:00, Room C)
ÁÂÀå: Â÷ºÀ¿¬, ³²È«¿ì
1. BIosynthesis, secretion and action of insulin ¹ÚÁ¤Çö (ÀÎÁ¦ÀÇ´ë)
2. Insulin preparation and side effects ¼Ûº¹·Ê (°­³²¼º¸ðº´¿ø)
3. Àν¶¸°ÀÇ Àå¾Ö¿äÀÎ Á¤¹ÌÇö (°í´ë¾È¾Ïº´¿ø)
4. Àν¶¸° Ä¡·á: ½ÇÁ¦ÀûÀÎ Áöħ ¹Úż± (ÀüºÏÀÇ´ë)
5. Àν¶¸°Ä¡·á¿Í ÀÓ»ó¿µ¾ç¿ä¹ý (Insulin therapy & MNT) ±Ç¹Ì¶ó (¼­¿ï´ëº´¿ø)
6. Àν¶¸°ÆßÇÁ Ä¡·á (Insulin pump therapy) ¼Û¿µµæ (Àϻ꺴¿ø)
¼ö·ÃÀ§¿øÈ¸ ¿¬¼ö°­Á (Sat. 10, 14:10~16:10, Room A)
ÁÂÀå: Á¶¿ë¿í, ¹Î°æ¿Ï
1. ´ç´¢º´ ´ëÇ÷°ü ÇÕº´ÁõÀÇ ¹ßº´±âÀü Á¤Àΰæ (°æÈñÀÇ´ë)
2. ºñ¸¸ÀÇ Ä¡·á ¹Ú¼®¿ø (Æ÷õÁß¹®ÀÇ´ë)
3. ´ç´¢º´ ȯÀÚÀÇ °íÇ÷¾Ð °ü¸® Á¶¿µ¹Î (¼­¿ïÀÇ´ë)
4. ´ç´¢º´ ȯÀÚÀÇ °íÁöÇ÷Áõ Ä¡·á ±èÈ¿Á¤ (À»ÁöÀÇ´ë)
½Äǰ¿µ¾çÀ§¿øÈ¸ ½ÉÆ÷Áö¾ö
ÁÖÁ¦: ´ç´¢º´°ú À½½Ä¹®È­
(Sat. 10, 11:10~13:10, Room C)
ÁÂÀå: ±è¿ë¼º, À¯Çý¼÷
1. ½Ä¹®È­ÀÇ ¿ª»çÀû ¹è°æ°ú Áúº´ ±è¿µ¼³ (°æÈñÀÇ´ë)
2. À½½Ä±ÃÇÕÀÇ È°¿ë ÀÌÃáÀÚ (ÀÎÇÏ´ë ½Äǰ¿µ¾çÇаú)
3. ±âÈ£½Äǰ°ú ´ç´¢ ÀÌ¿µ¶õ (°­³²¼º½Éº´¿ø)
Áø´Ü¼ÒÀ§¿øÈ¸ ½ÉÆ÷Áö¾ö
ÁÖÁ¦: ´çÈ­Ç÷»ö¼Ò Ç¥ÁØÈ­
(Fri. 9, 08:20~09:20, Room A(I))
ÁÂÀå: Á¤ÃáÈñ
1. ´çÈ­Ç÷»ö¼Ò Ç¥ÁØÈ­ÀÇ Çʿ伺 ÀÌÀºÁ¤ (¼º±Õ°üÀÇ´ë)
2. Çì¸ð±Û·Îºó A1C Ç¥ÁØÈ­ steering committee±¸¼º °èȹ ¼º¿¬¾Æ (ÀÌÈ­ÀÇ´ë)
3. HbA1c °Ë»çÀÇ ±¹³» ÇöȲ ¹× Ç¥ÁØÈ­ ¹æÇâ È«±â¼÷ (ÀÌÈ­ÀÇ´ë)
Ä¡·á¼ÒÀ§¿øÈ¸ ½ÉÆ÷Áö¾ö
ÁÖÁ¦: °æ±¸Ç÷´ç°­ÇÏÁ¦´Â ½ÉÇ÷°ü Áúȯ ¹ß»ý¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â°¡?
(Fri. 9, 08:00~09:20, Room A(II))
ÁÂÀå: ¿ìÁ¤ÅÃ
1. ¼³Æù¿ä¼ÒÁ¦, ¸ÞÆ®Æ÷¸£¹Î°ú ½ÉÇ÷°ü Áúȯ ¹ß»ý °í°üÇ¥ (Á¦ÁÖÀÇ´ë)
2. TZD Á¦Á¦¿Í ½ÉÇ÷°ü Áúȯ ¹ß»ý Â÷ºÀ¼ö (¿¬¼¼ÀÇ´ë)
3. ÆÐ³Î ÅäÀÇ ¹Úż± (ÀüºÏÀÇ´ë),
¹ÚÁ¤Çö (ÀÎÁ¦ÀÇ´ë),
¾È±ÔÁ¤ (°æÈñÀÇ´ë),
±è¼ºÈÆ (°üµ¿ÀÇ´ë)
´ç±â¿¬ TFT ½ÉÆ÷Áö¾ö
ÁÖÁ¦: ´ç´¢º´ ±âÃÊÅë°è¿¬±¸TFT º¸°í¼­ ¹ß°£ ¹× 2007³â 2Â÷ Àü±¹Á¶»ç
        ¿¹ºñ°á°ú º¸°í
(Fri. 9, 08:20~09:20, Room B)
ÁÂÀå: ¼ÕÈ£¿µ, ¹é¼¼Çö
1. ´ç´¢º´ ±âÃÊÅë°è¿¬±¸ TFT º¸°í¼­ ¹ß°£ : °æ°úº¸°í ¹ÚÀ̺´ (°¡ÃµÀÇ´ë)
2. 2007³â ´ç´¢º´±âÃÊÅë°è¿¬±¸ TFT Á¦2Â÷ Àü±¹Á¶»ç ¿¹ºñ°á°ú º¸°í ±èÀç¿ë (°Ç°­º¸Çè½É»çÆò°¡¿ø)
¿ªÇмÒÀ§¿øÈ¸ ½ÉÆ÷Áö¾ö
ÁÖÁ¦: ±¹³» Á¦2Çü ´ç´¢º´ ȯÀÚÀÇ ´Ü¸éÀû ¿ªÇבּ¸
(Fri. 9, 08:20~09:20, Room C)
ÁÂÀå: À¯ÇüÁØ, ÀÌÀαÔ
1. Çѱ¹ÀÎ Á¦2Çü ´ç´¢º´ ȯÀÚ¿¡¼­ ºñ¸¸ À¯º´·ü ¾ÈÀ¯¹è (°¡Å縯ÀÇ´ë)
2. ´ç´¢º´ ȯÀÚ¿¡¼­ ´ë»çÁõÈıºÀÇ À¯º´·ü ±è´ëÁß (¾ÆÁÖÀÇ´ë)
3. ´ç´¢º´ ÇÕº´Áõ ÀÓ¼ö (¼­¿ïÀÇ´ë)
4. ¾à¹° »ç¿ë½ÇÅ ¹× °ü¸®ÇöȲ Á¤Àΰæ (°æÈñÀÇ´ë)
´ë»çÁõÈıº ¼Ò¿¬±¸È¸ ½ÉÆ÷Áö¾ö
ÁÖÁ¦: Environmental factors and treatment targets of metabolic syndrome
(Sat. 10, 08:00~09:40, Room A(I))
ÁÂÀå: ÀÌÈ«±Ô, ÀÌÇöö
1. The endocannabinoid system: Treatment target of metabolic syndrome Matthias Bluher
(University of Leipzig, Germany)
2. The role of CB1 on pro-inflammatory activities of macrophages ÇѱâÈÆ (¿ï»êÀÇ´ë)
3. Application of DRE-CALUX bioassay for the dioxin like chemicals ½Å¿î¿ë (ÀÌÈ­¿©´ë ¾àÇаú)
Ç÷°ü¼¼Æ÷ ¼Ò¿¬±¸È¸ ½ÉÆ÷Áö¾ö
ÁÖÁ¦: Vascular cells research in diabetic retinopathy
(Sat. 10, 08:00~09:40, Room A(II))
ÁÂÀå: À¯ÇüÁØ, ÀÌÀαÔ
1. ´ç´¢º´¼º ¸Á¸·Ç÷°ü¿¡¼­ GPI-anchored ´Ü¹éÁúÀÇ ¿ªÇÒ ¹Ú¿ë½Ä (°æÈñÀÇ´ë)
2. New approach for retinal vascular complication in
   animal model
¼Õ¼®¸¸ (ºÎ»êÀÇ´ë)
3. Innovations for the treatment of diabetic retinopathy Hitoshi Takagi
(Kyoto University, Japan)
½Å°æº´Áõ ¼Ò¿¬±¸È¸ ½ÉÆ÷Áö¾ö (Sat. 10, 08:20~09:40, Room B)
ÁÂÀå: Â÷ºÀ¿¬, Á¶Á¤±¸
1. Treatment of diabetic neuropathy in the pathophysiologic background
Dan Ziegler (The Heinrich Heine University, Germany)
2. Çѱ¹ÀÎ ´ç´¢º´¼º ¸»ÃʽŰæÁõÀÇ ¿ªÇÐÀû Ư¡ ±èµ¿¼± (ÇѾçÀÇ´ë)
3. Impact on the quality of life of painful diabetic neuropathy in Korea ±èÁ¾È­ (¼¼Á¾º´¿ø)
¿îµ¿ ¼Ò¿¬±¸È¸ ½ÉÆ÷Áö¾ö (Sat. 10, 08:00~09:40, Room C)
ÁÂÀå: ¹Ú¼º¿ì, ¼ÕÇö½Ä
1. Should we measure waist circumference vs. BMI, waist-hip ratio? Àå»ó¾Æ (°¡Å縯ÀÇ´ë)
2. Beneficial effects of exercise - The role of myokines Ãְ湬 (°í·ÁÀÇ´ë)
3. Can a physically active lifestyle really prevent type 2 diabetes? ¹Úö¿µ (¼º±Õ°üÀÇ´ë)
4. Resistance training- Bring on the heavy weights? ¹Î°æ¿Ï (À»ÁöÀÇ´ë)
³ëÀδ索º´ ¼Ò¿¬±¸È¸ ½ÉÆ÷Áö¾ö
ÁÖÁ¦: Clinical Aspects in Elderly Diabetes
(Sat. 10, 11:10~13:10, Room B)
ÁÂÀå: ¾ÈÀ¯Çå, ÀåÇÐö
1. Overview of cardiovascular disease in elderly diabetic ÃÖ¼ºÈñ (¼­¿ïÀÇ´ë)
2. Management of renal impairment in elderly patients with diabetes Á¶µ¿Çõ (Àü³²ÀÇ´ë)
3. Psychiatric disorders among older adults with diabetes À̵¿¿ì (ÀÎÁ¦ÀÇ´ë)
4. ³ëÀÎ ´ç´¢º´ ȯÀÚÀÇ °íÇ÷¾Ð Ä¡·á ±èÀÎÁÖ (ºÎ»êÀÇ´ë)
°£È£ºÐ°ú ½ÉÆ÷Áö¾ö (Fri. 9, 15:10~17:10, Room C)
ÁÂÀå: È«¸íÈñ, ÃÖÁ¤¼÷
1. ´ç´¢ ¹ß°ü¸® ÀÚ°¡ ½Çõ±³À°ÀÌ ´ç´¢º´ ȯÀÚÀÇ ¹ß°ü¸® Áö½Ä, ÀÚ°¡°£È£ ÀÌÇ൵¿¡
    ¹ÌÄ¡´Â ¿µÇâ
³ë¼±¼÷ (»ï¼º¼­¿ïº´¿ø)
2. ´ç´¢Ä·ÇÁ¸¦ ÀÌ¿ëÇÑ ¹Ýº¹ÀûÀÎ ´ç´¢±³À° ÇÁ·Î±×·¥ÀÌ ³ëÀÎ ´ç´¢º´ ȯÀÚ¿¡°Ô
    ¹ÌÄ¡´Â È¿°ú
ÃÖ±ÝÈñ (ºÎ»ê¼º¸ðº´¿ø)
3. Á¦2Çü ´ç´¢º´ ȯÀÚÀÇ Ç÷´çÃøÁ¤, ½ÄÀÌ, ¿îµ¿, ÀÚ±âÈ¿´É°¨ÀÇ Ç÷°üÇÕº´Áõ¿¡ ´ëÇÑ
    ¿¹Ãø·Â
ÇÏÁ¤¹Ì (ºÎ»ê´ëÇб³º´¿ø)
4. ÄÄÇ»ÅÍ ±×·¡ÇÈÀ» ÀÌ¿ëÇÑ ÀÚ°¡ Ç÷´çÃøÁ¤±â »ç¿ë¿¡ µû¸¥ Ç÷´çÁ¶ÀýÀÇ È¿°ú ¹ÚºÀ¼÷ (¿øÁֱ⵶º´¿ø)
Satellite Symposia
Satellite Symposium I (Thu. 8, 17:30~18:10, Paradise)
ÁÂÀå: ±è¿ë±â
Sanofi-Aventis
Promising role of ARB in the treatment of metabolic syndrome & type 2 diabetes À̹®±Ô (¼º±Õ°üÀÇ´ë)
Satellite Symposium II (Thu. 8, 18:10~18:50, Paradise)
ÁÂÀå: ±èº¸¿Ï
Norvatis
The clinical relationship between insulin resistance and glycemic control in type 2 diabetes
Steven M. Haffner (University of Texas, USA)
Sponsored by G.S.K.
Breakfast Symposium I (Fri. 9, 07:20~08:10, Room B)
ÁÂÀå: ½Å¼øÇö
TZD efficacy and CV outcomes ¿À½ÂÁØ (°æÈñÀÇ´ë)
Sponsored by Lilly
Breakfast Symposium II (Sat. 10, 07:20~08:10, Room B)
ÁÂÀå: Á¤¹Î¿µ
Current treatment guideline of diabetes ¹Ú¼®¿ø (Æ÷õÁß¹®ÀÇ´ë)
Sponsored by Daewoong
Sponsored Lecture I (Fri. 9, 14:00~15:00, Room B)
ÁÂÀå: ÀÌÅÂÈñ
Diabetic retinopathy: Prevention and treatment ¹ÚÁ¤Çö (ÀÎÁ¦ÀÇ´ë)
Sponsored by Astra Zeneca
Sponsored Lecture II (Fri. 9, 14:00~15:00, Room C)
ÁÂÀå: ±è¿µ°Ç
1. The burden of hypertension & exploring a rationale: CCB/ARB ÀÌÇü¿ì (¿µ³²ÀÇ´ë)
2. Changing the landscape of BP management ±èÀÎÁÖ (ºÎ»êÀÇ´ë)
Luncheon Lecture I (Fri. 9, 13:00~14:00, Room A)
ÁÂÀå: ¹ÎÇå±â
ÁÖÁ¦: Breaking the cardiovascular disease continuum in diabetic patients
1. Sulphonylureas revisited : Focus on cardiovascular safety and side effects
Jorgen Rungby (Aarhus University Hospital, Denmark)
2. Tight BP control management in diabetic patients: What ADVANCE tells us
Pavel Hamet (University of Montreal, Canada)
Sponsored by Servier
Luncheon Lecture II (Fri. 9, 13:00~14:00, Room B)
ÁÂÀå: Çã°©¹ü
Novel long acting insulin analogues Roger Chen
(Concord Hospital, Australia)
Sponsored by Novo Nordisk
Luncheon Lecture III (Sat. 10, 13:20~14:10, Room A)
ÁÂÀå: À̱¤¿ì
JANUVIA - The 1st physiologic glucose regulator for optimal treatment of type 2 diabetes
Russell Scott (Christchurch Hospital, New Zealand)
Sponsored by MSD
Luncheon Lecture IV (Sat. 10, 13:20~14:10, Room B)
ÁÂÀå: °­¼º±¸
The incretin therapy concept - A revolution in the treatment of type 2 diabetes
Wolfgang E. Schmidt (Ruhr-University Bochum, Germany)
Sponsored by Handock & Novartis